↓ Skip to main content

Dove Medical Press

Article Metrics

Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder

Overview of attention for article published in Pharmacogenomics and Personalized Medicine, July 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
16 Mendeley
Title
Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder
Published in
Pharmacogenomics and Personalized Medicine, July 2017
DOI 10.2147/pgpm.s140700
Pubmed ID
Authors

Mikhail Sergeevich Zastrozhin, Vadim Markovich Brodyansky, Valentin Yurievich Skryabin, Elena Anatolievna Grishina, Dmitry Vladimirovich Ivashchenko, Kristina Anatolievna Ryzhikova, Ludmila Mikhaylovna Savchenko, Alexander Olegovich Kibitov, Evgeny Alekseevich Bryun, Dmitry Alekseevich Sychev

Abstract

Antipsychotic action of haloperidol is due to blockade of D2 receptors in the mesolimbic dopamine pathway, while the adverse drug reactions are associated with striatal D2 receptor blockade. Contradictory data concerning the effects of genetic polymorphisms of genes encoding these receptors and associated structures (catechol-O-methyltransferase [COMT], glycine transporter and gene encoding the density of D2 receptors on the neuronal membrane) are described. The objectives of this study were to evaluate the correlation between DRD2, SLC6A3 (DAT) and COMT genetic polymorphisms and to investigate their effect on the development of adverse drug reactions in patients with alcohol-use disorder who received haloperidol. The study included 64 male patients (average age 41.38 ± 10.14 years, median age 40 years, lower quintile [LQ] 35 years, upper quintile [UQ] 49 years). Bio-Rad CFX Manager™ software and "SNP-Screen" sets of "Syntol" (Russia) were used to determine polymorphisms rs4680, rs1800497, rs1124493, rs2242592, rs2298826 and rs2863170. In every "SNP-Screen" set, two allele-specific hybridizations were used, which allowed to determine two alleles of studied polymorphism separately on two fluorescence channels. Results of this study detected a statistically significant difference in the adverse drug reaction intensity in patients receiving haloperidol with genotypes 9/10 and 10/10 of polymorphic marker SLC6A3 rs28363170. In patients receiving haloperidol in tablets, the increases in the UKU Side-Effect Rating Scale (UKU) score of 9.96 ± 2.24 (10/10) versus 13 ± 2.37 (9/10; p < 0.001) and in the Simpson-Angus Scale (SAS) score of 5.04 ± 1.59 (10/10) versus 6.41 ± 1.33 (9/10; p = 0.006) were revealed. Polymorphism of the SCL6A3 gene can affect the safety of haloperidol, and this should be taken into account during the choice of drug and its dosage regimen.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 25%
Student > Doctoral Student 2 13%
Student > Master 2 13%
Unspecified 1 6%
Student > Bachelor 1 6%
Other 2 13%
Unknown 4 25%
Readers by discipline Count As %
Medicine and Dentistry 4 25%
Neuroscience 3 19%
Biochemistry, Genetics and Molecular Biology 2 13%
Agricultural and Biological Sciences 1 6%
Psychology 1 6%
Other 1 6%
Unknown 4 25%